{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:06:47Z","timestamp":1788883607617,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103048","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:30:37Z","timestamp":1785799837000},"page":"103048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antisense oligonucleotide selection scheme for rare Duchenne muscular dystrophy mutations: Application to DMD exon 16 skipping"],"prefix":"10.1016","volume":"37","author":[{"given":"Marine","family":"Geoffroy-Guiraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriaque","family":"Beley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephany","family":"Campuzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu Huyen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Blaszykowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-7454","authenticated-orcid":false,"given":"Simon","family":"Guiraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103048_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The Pathogenesis and Therapy of Muscular Dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"10.1016\/j.omtn.2026.103048_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2026.103048_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/mus.880100212","article-title":"Management of end stage respiratory failure in Duchenne muscular dystrophy","volume":"10","author":"Bach","year":"1987","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2026.103048_bib4","doi-asserted-by":"crossref","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","article-title":"Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2026.103048_bib5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/323646a0","article-title":"Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene","volume":"323","author":"Monaco","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103048_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103048_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.omtn.2026.103048_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110242","article-title":"Dystrophin deficiency impairs cell junction formation during embryonic myogenesis from pluripotent stem cells","volume":"27","author":"Mozin","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2026.103048_bib9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103048_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/brainsci5030275","article-title":"Nonmechanical Roles of Dystrophin and Associated Proteins in Exercise, Neuromuscular Junctions, and Brains","volume":"5","author":"Nichols","year":"2015","journal-title":"Brain Sci."},{"key":"10.1016\/j.omtn.2026.103048_bib11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/0140-6736(90)91364-G","article-title":"Dystrophin function","volume":"335","author":"Emery","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.103048_bib12","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13543784.2024.2313105","article-title":"Duchenne muscular dystrophy: promising early-stage clinical trials to watch","volume":"33","author":"Tang","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.omtn.2026.103048_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-0716-4730-1_3","article-title":"An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases","volume":"2964","author":"Rodrigues","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2026.103048_bib15","first-page":"43","article-title":"Read-through approach for stop mutations in Duchenne muscular dystrophy. An update","volume":"40","author":"Politano","year":"2021","journal-title":"Acta Myol."},{"key":"10.1016\/j.omtn.2026.103048_bib16","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.ymthe.2025.03.065","article-title":"The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy","volume":"33","author":"Bengtsson","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103048_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological advances for treatment in Duchenne muscular dystrophy","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.omtn.2026.103048_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103048_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/genes15111489","article-title":"An Updated Analysis of Exon-Skipping Applicability for Duchenne Muscular Dystrophy Using the UMD-DMD Database","volume":"15","author":"Leckie","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.omtn.2026.103048_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031303","article-title":"30 Years Since the Proposal of Exon Skipping Therapy for Duchenne Muscular Dystrophy and the Future of Pseudoexon Skipping","volume":"26","author":"Matsuo","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103048_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtn.2026.103048_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtn.2026.103048_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2024.10.005","article-title":"Safety and efficacy of viltolarsen treatment in patients with Duchenne muscular dystrophy: A retrospective study with 3-year follow-up","volume":"47","author":"Funato","year":"2025","journal-title":"Brain Dev."},{"key":"10.1016\/j.omtn.2026.103048_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040912","article-title":"Casimersen (AMONDYS 45): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy","volume":"12","author":"Assefa","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2026.103048_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1261\/rna.079498.122","article-title":"Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics","volume":"29","author":"Pradeep","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2026.103048_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103048_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103048_bib28","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf241","article-title":"AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy","volume":"53","author":"Etxaniz","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib30","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"Torres-Masjoan","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103048_bib31","first-page":"12","article-title":"Conformationally Restricted Oligonucleotide Analogues 'Made in Bern': A Mini Review","volume":"55","author":"CJ","year":"2001","journal-title":"Chimia"},{"key":"10.1016\/j.omtn.2026.103048_bib32","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/nar\/gkf412","article-title":"Antisense properties of tricyclo-DNA","volume":"30","author":"Renneberg","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103048_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/nat.2018.0773","article-title":"Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model","volume":"29","author":"Echevarr\u00eda","year":"2019","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.103048_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/nar\/gkab1199","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"50","author":"Relizani","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtn.2019.11.020","article-title":"Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy","volume":"19","author":"Aupy","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103048_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omtn.2023.03.009","article-title":"Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mdx52 mice","volume":"32","author":"Saoudi","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103048_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123243","article-title":"Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model","volume":"11","author":"Doisy","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2026.103048_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2023.0046","article-title":"Impact of the Inhibition of Organic Anion Transporter on Tricyclo-DNA-Mediated Exon Skipping in the mdx Mouse Model","volume":"33","author":"Bizot","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.103048_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/nat.2024.0085","article-title":"Combined 20-Hydroxyecdysone and Antisense-Mediated Exon Skipping Improve Functional Outcomes in a Mouse Model of Duchenne Muscular Dystrophy","volume":"35","author":"Blitek","year":"2025","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.103048_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26062583","article-title":"Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice","volume":"26","author":"Phongsavanh","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103048_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050702","article-title":"Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model","volume":"12","author":"Bizot","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2026.103048_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/humu.9477","article-title":"Deletion of exon 16 of the dystrophin gene is not associated with disease","volume":"28","author":"Schwartz","year":"2007","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2026.103048_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.mt.6300006","article-title":"The influence of antisense oligonucleotide length on dystrophin exon skipping","volume":"15","author":"Harding","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103048_bib45","first-page":"410","article-title":"Immunocytochemical study of dystrophin in muscle cultures from patients with Duchenne muscular dystrophy and unaffected control patients","volume":"132","author":"Miranda","year":"1988","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2026.103048_bib46","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/nar\/gkg616","article-title":"ESEfinder: A web resource to identify exonic splicing enhancers","volume":"31","author":"Cartegni","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib47","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1093\/nar\/gkg599","article-title":"Vienna RNA secondary structure server","volume":"31","author":"Hofacker","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97730-5","article-title":"Duchenne muscular dystrophy cell culture models created by CRISPR\/Cas9 gene editing and their application in drug screening","volume":"11","author":"Soblechero-Mart\u00edn","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103048_bib49","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1093\/nar\/gkaa164","article-title":"Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice","volume":"48","author":"Chappell","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103048_bib50","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1074\/jbc.M709410200","article-title":"Generation and characterization of transgenic mice with the full-length human DMD gene","volume":"283","author":"'t Hoen","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.103048_bib51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ymthe.2004.05.031","article-title":"Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides","volume":"10","author":"Bremmer-Bout","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103048_bib52","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","article-title":"Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide","volume":"2","author":"Henry","year":"2002","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omtn.2026.103048_bib53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5625\/lar.2016.32.2.79","article-title":"Reference values of clinical pathology parameters in cynomolgus monkeys (Macaca fascicularis) used in preclinical studies","volume":"32","author":"Park","year":"2016","journal-title":"Lab. Anim. Res."},{"key":"10.1016\/j.omtn.2026.103048_bib54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/10915810500208058","article-title":"Individual reference intervals of hematological and serum biochemical parameters in cynomolgus monkeys","volume":"24","author":"Koga","year":"2005","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.omtn.2026.103048_bib55","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41596-022-00790-8","article-title":"3D human induced pluripotent stem cell-derived bioengineered skeletal muscles for tissue, disease and therapy modeling","volume":"18","author":"Pinton","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2026.103048_bib56","article-title":"A Voyage on the Role of Nuclear Factor Kappa B (NF-kB) Signaling Pathway in Duchenne Muscular Dystrophy: An Inherited Muscle Disorder","volume":"16","author":"R","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.omtn.2026.103048_bib57","doi-asserted-by":"crossref","first-page":"C1244","DOI":"10.1152\/ajpcell.00182.2023","article-title":"Extracellular matrix contribution to disease progression and dysfunction in myopathy","volume":"325","author":"Long","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.omtn.2026.103048_bib58","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0960-8966(02)00088-3","article-title":"Multivariate evaluation of the functional recovery obtained by the overexpression of utrophin in skeletal muscles of the mdx mouse","volume":"12","author":"Gillis","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.103048_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389202911314020003","article-title":"Integrated analysis of transcriptomic and proteomic data","volume":"14","author":"Haider","year":"2013","journal-title":"Curr. Genom."},{"key":"10.1016\/j.omtn.2026.103048_bib60","first-page":"249","article-title":"A platform for personalized ASO therapeutics","volume":"24","author":"Crunkhorn","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103048_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/nat.2022.0060","article-title":"Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides","volume":"33","author":"Aartsma-Rus","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.103048_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120058","article-title":"In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy","volume":"10","author":"Echigoya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103048_bib63","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1089\/nat.2023.0038","article-title":"Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy","volume":"33","author":"Engelbeen","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.103048_bib64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-0716-2772-3_2","article-title":"Viltolarsen: From Preclinical Studies to FDA Approval","volume":"2587","author":"Roshmi","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2026.103048_bib65","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1096\/fj.13-232025","article-title":"DMD transcript imbalance determines dystrophin levels","volume":"27","author":"Spitali","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2026.103048_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtn.2026.103048_bib67","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103048_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193289","article-title":"A dystrophic Duchenne mouse model for testing human antisense oligonucleotides","volume":"13","author":"Veltrop","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103048_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.782333","article-title":"Recent Trends in Biofabrication Technologies for Studying Skeletal Muscle Tissue-Related Diseases","volume":"9","author":"Cho","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103048_bib70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s10038-017-0400-0","article-title":"A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR\/Cas9 and evaluation of antisense-mediated exon skipping","volume":"63","author":"Shimo","year":"2018","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.omtn.2026.103048_bib71","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1002\/jcsm.13094","article-title":"Engineered skeletal muscle recapitulates human muscle development, regeneration and dystrophy","volume":"13","author":"Shahriyari","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2026.103048_bib72","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.celrep.2018.03.091","article-title":"Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering","volume":"23","author":"Maffioletti","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.103048_bib73","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103048_bib74","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10974-019-09535-9","article-title":"What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?","volume":"40","author":"Wells","year":"2019","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.omtn.2026.103048_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/narmme\/ugag001","article-title":"Systemic distribution of tricyclo-DNA antisense oligonucleotide following intratracheal instillation in the mouse","volume":"3","author":"Laurent","year":"2026","journal-title":"NAR Mol. Med."},{"key":"10.1016\/j.omtn.2026.103048_bib76","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2005.10.016","article-title":"A signaling role for dystrophin: inhibiting skeletal muscle atrophy pathways","volume":"8","author":"Glass","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2026.103048_bib77","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s42003-022-03980-y","article-title":"The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction","volume":"5","author":"Wilson","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtn.2026.103048_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.1059021","article-title":"The importance of dystrophin and the dystrophin associated proteins in vascular smooth muscle","volume":"13","author":"Kaplan","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2026.103048_bib79","first-page":"93","article-title":"The role of dystrophin in the central nervous system: a mini review","volume":"24","author":"Sekiguchi","year":"2005","journal-title":"Acta Myol."},{"key":"10.1016\/j.omtn.2026.103048_bib80","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/awae384","article-title":"The role of dystrophin isoforms and interactors in the brain","volume":"148","author":"Tetorou","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2026.103048_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64999-3","article-title":"Intrinsic dysfunction in muscle stem cells lacking dystrophin begins during secondary myogenesis","volume":"16","author":"Esper","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103048_bib82","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jcsm.12665","article-title":"Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset","volume":"12","author":"Mournetas","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2026.103048_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110242","article-title":"Dystrophin deficiency impairs cell junction formation during embryonic myogenesis from pluripotent stem cells","volume":"27","author":"Mozin","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2026.103048_bib84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2044-5040-1-34","article-title":"Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders","volume":"1","author":"Mamchaoui","year":"2011","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.omtn.2026.103048_bib85","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","article-title":"Second-generation compound for the modulation of utrophin in the therapy of DMD","volume":"24","author":"Guiraud","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103048_bib86","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","article-title":"Single-pot, solid-phase-enhanced sample preparation for proteomics experiments","volume":"14","author":"Hughes","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2026.103048_bib87","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:07:49Z","timestamp":1788880069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126002192"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103048","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotide selection scheme for rare Duchenne muscular dystrophy mutations: Application to DMD exon 16 skipping","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103048"}}